What is the 13F Pro Quality Score for GILD?

13F Pro ranks GILEAD SCIENCES, INC. (GILD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View GILD's current score at https://13fpro.ai/research/GILD (free sign-up required for the full ranking).

Which hedge funds own the most GILD stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of GILD include BlackRock,, VANGUARD CAPITAL MANAGEMENT, FMR. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/GILD as soon as new 13F filings post.

Where does 13F Pro source GILD data?

All GILEAD SCIENCES, INC. fundamentals and ownership data come directly from SEC EDGAR. GILEAD SCIENCES, INC. files with the SEC under CIK 882095. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is GILD in?

GILEAD SCIENCES, INC. (GILD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives GILD's revenue?

Per GILEAD SCIENCES, INC.'s latest 10-Q filed with the SEC on 2026-05-07, the biggest revenue drivers are: HIV products ($5.0B, +10% YoY); Oncology ($810M, +7% YoY); Liver Disease ($767M, +1% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/GILD.

What are GILD's largest expenses?

GILEAD SCIENCES, INC.'s latest 10-Q reports these as the largest expense items: Cost of goods sold ($1,445M, -6% YoY); Selling, general and administrative expenses ($1,451M, +15% YoY); Research and development expenses ($1,372M, -1% YoY). Sourced directly from SEC EDGAR filing text for Q1 2026 (quarter ended March 31, 2026).

How often is GILD research updated on 13F Pro?

GILD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

GILEAD SCIENCES, INC.(GILD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 882095 GILD stock profile & AI dashboard →

13F Pro Quality Score

77.8/100

Rank #75 of 2,879 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

44.7/100

Profitability

91.7/100

Balance Sheet

92.5/100

Earnings Quality

99.8/100

Free Cash Flow

86.3/100

Institutional Flow

55.2/100

Revenue Scale

95.2/100

Dilution Risk

33.2/100

GILD Stock Analysis & AI Quality Score

AI stock analysis and institutional research for GILEAD SCIENCES, INC. (GILD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GILD at 77.8/100 on a 32-signal composite quality model, placing it at rank #75 of 2,879 stocks — the top 5% of the AI-ranked universe. GILD scores in the top quartile across earnings quality (99.8), revenue scale (95.2), balance sheet strength (92.5). Shareholder dilution risk is elevated at 33.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), GILEAD SCIENCES, INC. reports quarterly revenue of $7.0B, net income of $2.0B, an operating margin of 37.2%. Top institutional holders of GILD by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, FMR, based on the most recent SEC filings. GILD trades on the Nasdaq exchange and files with the SEC under CIK 882095. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GILD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GILEAD SCIENCES, INC. directly from SEC EDGAR. GILEAD SCIENCES, INC.'s 13F Pro composite quality score has ranged between 51 and 80 since 2021, currently 77.8 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about GILEAD SCIENCES, INC.

Quirks, history, and lore behind GILD — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · large-cap · listed on Nasdaq · headquartered in Northern California.
2
The Numbers
Annual revenue around $27 billion, with profit margins that most industries can only dream about — antiviral drugs are very, very good business.
3
The History
Founded in 1987, it spent years as a quiet biotech before transforming medicine in the 2010s with drugs so effective they essentially cured a previously incurable disease.
4
The Secret
Its hepatitis C franchise was once a $10-billion-a-year juggernaut — then it worked so well it nearly cured its own market out of existence.
5
The Lore
When COVID-19 hit, the world's eyes turned to its antiviral remdesivir — the first drug authorized to treat the disease in the U.S.
6
The Giveaway
The maker of Sovaldi, Harvoni, and the HIV treatment backbone Truvada — this Foster City giant essentially rewrote the rulebook on antiviral medicine.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving GILD's Business? Latest 10-Q Breakdown

✓ 27/27 datapoints verified

AI-extracted from GILEAD SCIENCES, INC.'s 10-Q filed 2026-05-07 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Total revenues grew 4% YoY to $7.0B driven by HIV and Trodelvy strength, while net income surged 54% to $2.0B on equity gains, though company expects $11.5B IPR&D charges in Q2 from recent acquisitions.

Biggest Revenue Drivers

Total revenue: $7.0B+4% YoY

HIV products$5.0B+10% YoY

Higher demand and average realized price, including Biktarvy switching gains and Descovy growth of +38%.

Oncology$810M+7% YoY

Trodelvy sales increased 37% on higher demand and favorable inventory; cell therapy declined 12% due to competitive headwinds.

Liver Disease$767M+1% YoY

Higher Livdelzi demand offset by lower HCV product sales and unfavorable inventory dynamics.

Veklury$144M-52% YoY

Lower COVID-19-related hospitalizations.

Other products$196M-6% YoY

Includes AmBisome and other marketed products.

Largest Expense Items

Cost of goods sold$1,445M-6% YoY

Product gross margin expanded to 79.2% from 76.7% due to royalty obligation expiration and favorable product mix.

Selling, general and administrative expenses$1,451M+15% YoY

Higher HIV promotional expenses and $63M equity donations to Gilead Foundation.

Research and development expenses$1,372M-1% YoY

Personnel costs flat; clinical studies decreased due to lower oncology activity, offset by higher virology manufacturing investment.

Acquired in-process research and development expenses$107M-58% YoY

Q1 2026 included $80M Suzhou Genhouse upfront; Q1 2025 included $250M LEO Pharma upfront.

Margins: Product gross margin improved 249 basis points to 79.2% YoY, driven by expiration of a royalty obligation and favorable product mix. Operating margin benefited from higher revenues and lower cost of goods sold, partially offset by increased SG&A spending on promotional activities.

Watch Items from the Filing

Three wholesalers (Cardinal Health, Cencora, McKesson) and affiliates represent ~60% of accounts receivable; inventory fluctuations in distribution channel cause quarterly earnings volatility.
Veklury sales down 52% YoY to $144M; revenue remains highly dependent on COVID-19 hospitalization rates and vaccine/treatment uptake, creating forecast uncertainty.
Company expects $11.5B in Acquired IPR&D charges in Q2 2026 from Arcellx, Tubulis, and Ouro acquisitions, resulting in expected net loss for full year 2026.
Biktarvy selected for Maximum Fair Price negotiation under Medicaid effective 2028; anticipated negotiated Medicare price substantially lower than current, increasing rebate and 340B obligations.
Florida ADAP removed Biktarvy from formulary and restricted Descovy access in March 2026; additional state ADAPs may implement similar cost-containment measures affecting patient access.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$7.0B

Net Income

Q1 2026

$2.0B

Free Cash Flow

Q1 2026

$2.4B

Operating Margin

Q1 2026

37.2%

D/E Ratio

Q1 2026

1.05

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+2.4% YoY

$29.44BFY 2025

FY22 $27.28BFY23 $27.12BFY24 $28.75BFY25 $29.44B

Net Income

+1672.9% YoY

$8.51BFY 2025

FY22 $4.59BFY23 $5.67BFY24 $480.0MFY25 $8.51B

Operating Income

+503.0% YoY

$10.02BFY 2025

FY22 $7.33BFY23 $7.61BFY24 $1.66BFY25 $10.02B

EPS (Diluted)

+1684.2% YoY

$6.78FY 2025

FY22 $3.64FY23 $4.50FY24 $0.38FY25 $6.78

Total Assets

+0.0% YoY

$59.02BFY 2025

FY22 $63.17BFY23 $62.13BFY24 $58.99BFY25 $59.02B

Total Debt

+0.7% YoY

$30.55BFY 2025

FY22 $29.77BFY23 $28.58BFY24 $30.34BFY25 $30.55B

Op. Cash Flow

-7.5% YoY

$10.02BFY 2025

FY22 $9.07BFY23 $8.01BFY24 $10.83BFY25 $10.02B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019
Revenue	$29.44B +2.4%	$28.75B +6.0%	$27.12B -0.6%	$27.28B +10.5%	$24.69B +10.0%	$22.45B
Net Income	$8.51B +1672.9%	$480.0M -91.5%	$5.67B +23.4%	$4.59B +3633.3%	$123.0M -97.7%	$5.39B
Operating Income	$10.02B +503.0%	$1.66B -78.1%	$7.61B +3.8%	$7.33B +80.1%	$4.07B -5.0%	$4.29B
EPS (Diluted)	$6.78 +1684.2%	$0.38 -91.6%	$4.50 +23.6%	$3.64 +3540.0%	$0.10 -97.6%	$4.22
Total Assets	$59.02B +0.0%	$58.99B -5.0%	$62.13B -1.7%	$63.17B -7.7%	$68.41B +11.0%	$61.63B
Total Debt	$30.55B +0.7%	$30.34B +6.1%	$28.58B -4.0%	$29.77B -19.3%	$36.92B +36.3%	$27.09B
Operating Cash Flow	$10.02B -7.5%	$10.83B +35.2%	$8.01B -11.8%	$9.07B +11.1%	$8.17B -10.7%	$9.14B

AI Insight: GILD Financial Trends

Gilead reduced debt by $5.8B while equity grew 29% since Q2 2024, but Q1 2026 revenue fell 12% sequentially and operating cash flow remains volatile.

• Total debt fell from $26,968M (Q2 2024) to $24,800M (Q1 2026); equity rose 29% to $23,515M, improving balance sheet strength.

• Operating income averaged $2,443M over latest four quarters; Q3 2025 peaked at $3,327M but Q4 2025 declined to $1,984M.

• Net income surged to $3,052M in Q3 2025 but moderated to $2,021M in Q1 2026, showing inconsistent profitability.

⚠ Q1 2026 revenue of $6,960M marks 12% sequential decline from Q4 2025 and lowest level in eight quarters — trend reversal risk.

⚠ Operating cash flow volatility persists: $827M (Q2 2025) to $4,309M (Q3 2024) — working capital management inconsistent.

Get alerted when GILD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for GILEAD SCIENCES, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of GILD

BlackRock, Inc.
$16.6B119,010,973 sh
VANGUARD CAPITAL MANAGEMENT LLC
$11.2B80,654,776 sh
FMR LLC
$10.0B71,906,290 sh
STATE STREET CORP
$8.3B59,858,585 sh
Capital World Investors
$5.8B41,283,933 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$4.9B35,129,465 sh
GEODE CAPITAL MANAGEMENT, LLC
$4.1B29,726,052 sh
Capital Research Global Investors
$3.8B27,127,533 sh
DODGE & COX
$3.4B24,250,826 sh
MORGAN STANLEY
$3.2B23,299,295 sh

Fund	Value	Shares
BlackRock, Inc.	$16.6B	119,010,973
VANGUARD CAPITAL MANAGEMENT LLC	$11.2B	80,654,776
FMR LLC	$10.0B	71,906,290
STATE STREET CORP	$8.3B	59,858,585
Capital World Investors	$5.8B	41,283,933
VANGUARD PORTFOLIO MANAGEMENT LLC	$4.9B	35,129,465
GEODE CAPITAL MANAGEMENT, LLC	$4.1B	29,726,052
Capital Research Global Investors	$3.8B	27,127,533
DODGE & COX	$3.4B	24,250,826
MORGAN STANLEY	$3.2B	23,299,295

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put GILD on your watchlist

Track score changes the day GILEAD SCIENCES, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is GILD a good stock to buy?

13F Pro's AI-powered analysis of GILEAD SCIENCES, INC. (GILD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GILD are available on the GILD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own GILD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GILD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of GILEAD SCIENCES, INC.'s investment landscape.